Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Highlights in the myeloma field to come at ASH 2020

Enrique Ocio • 25 Nov 2020
ASH 2020
Multiple Myeloma Antibodies CAR-T

Enrique M. Ocio, MD, PhD, Marqués de Valdecilla University Hospital, Santander, Spain, shares what highlights there are to look forward to in the multiple myeloma field at ASH 2020. Immunotherapy will be the leading topic for myeloma, he says, with many presentations and sessions surrounding CAR-T cells, novel bispecific antibodies, and antibody-drug conjugates. He is also looking forward to seeing the results of allogeneic CAR T-cell studies in myeloma. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

More from Enrique Ocio

2:18
Efficacy and safety results from the ANCHOR trial
Enrique Ocio • 29 Sep 2023
2:03
The safety and efficacy of Isa-VRd in patients with transplant-ineligible NDMM
Enrique Ocio • 29 Sep 2023
1:27
Clonal hematopoiesis in multiple myeloma and implications for therapy
Enrique Ocio • 29 Sep 2023
Key myeloma highlights from EHA 2023
Enrique Ocio et al. • 9 Jun 2023

Related Videos

1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals